Sarepta Therapeutics (SRPT) EBIT (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly EBIT of $358.4 million for Q1 2026, up 219.32% year-over-year from $112.2 million in Q1 2025, and up 187.09% quarter-over-quarter from -$411.6 million in Q4 2025.
Sarepta Therapeutics (SRPT) EBIT (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' EBIT history runs 17 years deep, the most recent figure standing at $358.4 million for Q1 2026.
- In Q1 2026, EBIT rose 219.32% year-over-year to $358.4 million; the TTM figure through Mar 2026 stood at -$41.0 million (up 65.05% YoY), while the FY2025 annual figure was -$699.8 million, down 420.88% from the prior year.
- EBIT for Q1 2026 stood at $358.4 million, up from -$411.6 million in the prior quarter.
- The five-year high for EBIT was $358.4 million in Q1 2026, with the low at -$411.6 million in Q4 2025.
- The 5-year median for EBIT is -$86.9 million (2022), against an average of -$54.5 million.
- Peak annual rise in EBIT reached 16587.45% in 2025, while the deepest fall reached 960.58% in 2025.
- Sarepta Therapeutics' EBIT stood at -$106.8 million in 2022, then surged by 123.05% to $24.6 million in 2023, then soared by 556.57% to $161.7 million in 2024, then sank by 354.56% to -$411.6 million in 2025, then surged by 187.09% to $358.4 million in 2026.
- Business Quant data shows SRPT's EBIT at $358.4 million in Q1 2026, -$411.6 million in Q4 2025, and -$103.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 13.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.29 Mn |
| Mar 31, 2026 | 358.43 Mn |
| Dec 31, 2025 | -411.58 Mn |
| Sep 30, 2025 | -103.39 Mn |
| Jun 30, 2025 | 115.58 Mn |
| Mar 31, 2025 | -300.39 Mn |
| Dec 31, 2024 | 161.68 Mn |
| Sep 30, 2024 | 22.20 Mn |
| Jun 30, 2024 | -701,000.00 |
| Mar 31, 2024 | 34.91 Mn |
| Dec 31, 2023 | 24.63 Mn |
| Sep 30, 2023 | -20.84 Mn |
| Jun 30, 2023 | -133.52 Mn |
| Mar 31, 2023 | -138.09 Mn |
| Dec 31, 2022 | -106.83 Mn |
| Sep 30, 2022 | -131.36 Mn |
| Jun 30, 2022 | -211.13 Mn |
| Mar 31, 2022 | -86.88 Mn |
| Dec 31, 2021 | -105.81 Mn |
| Sep 30, 2021 | -34.46 Mn |